• SPX
  • $6,001.35
  • 0.1 %
  • $5.81
  • DJI
  • $44,293.13
  • 0.69 %
  • $304.14
  • N225
  • $39,376.09
  • -0.4 %
  • -$157.23
  • FTSE
  • $8,044.55
  • -0.99 %
  • -$80.64
  • IXIC
  • $19,298.76
  • 0.06 %
  • $11.99
Royalty Pharma plc (RPRX) Stock Price, News & Analysis

Royalty Pharma plc (RPRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$26.37

$0.16

(0.59%)

Day's range
$26.12
Day's range
$26.6
50-day range
$26.08
Day's range
$29.36
  • Country: US
  • ISIN: GB00BMVP7Y09
52 wk range
$25.2
Day's range
$31.66
  • CEO: Mr. Pablo Gerardo Legorreta
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.63
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (RPRX)
  • Company Royalty Pharma plc
  • Price $26.37
  • Changes Percentage (0.59%)
  • Change $0.16
  • Day Low $26.12
  • Day High $26.60
  • Year High $31.66

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

  • Last Earnings 10/11/2024
  • Ex-Dividend for 5/16 Dividend 11/15/2024
  • Dividend Payable 12/10/2024
  • Today N/A
  • Next Earnings (Estimated) 02/12/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $51.00
  • High Stock Price Target $51.00
  • Low Stock Price Target $28.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $1.78
  • Trailing P/E Ratio 15.43
  • Forward P/E Ratio 15.43
  • P/E Growth 15.43
  • Net Income $1.13 B

Income Statement

Quarterly

Annual

Latest News of RPRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.